Navigation Links
Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights
Date:2/12/2010

- Payment to Bioniche of US$8M by Endo Pharmaceuticals -

BELLEVILLE, ON, Feb. 12 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, today announced that it has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals ( ENDP) for exclusive rights to develop and market Bioniche's proprietary product for non-muscle-invasive bladder cancer in North America. The achievement of these milestones triggers a total payment of US$8 million to Bioniche from Endo.

Endo Pharmaceuticals has also elected to exercise its option for exclusive rights to develop and market the product globally. As a result of the decision, Endo will all assume all external development expenses for the product.

"We are pleased with this decision by Endo," stated Graeme McRae, Chairman, President and CEO of Bioniche Life Sciences Inc. "We look forward to ongoing collaboration in addressing the global market opportunity for our bladder cancer product, as well as effectively completing the clinical development program and achieving product registrations in global jurisdictions."

Under the licensing agreement, Bioniche has the potential to receive a total of US$110 million in payments associated with the achievement of certain clinical, regulatory and commercial milestones. The achievement of the first milestone of US$6 million was announced by the Company in November 2009. Future milestones will be announced as they are achieved and, with its exclusive manufacturing supply contract, Bioniche will also receive a net-sales-based revenue stream upon product approval.

Bioniche's patented intravesical formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed for the treatment of non-muscle-invasive bladder cancer (Urocidin(TM)) is undergoing a U.S. Food and Drug Administration (FDA) fast tracked Phase III registration study of the product for the treatment-refractory indication. Future plans to further develop Urocidin(TM) are being defined and will be disclosed by Endo.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Pharma Acquires Duraclon(R) (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP
2. Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection
3. Bioniche Reports Fiscal 2009 Year-End Results
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
5. Bioniche Repays Revolving Credit Facility
6. Bioniche Provides a Corporate Update
7. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
8. Bioniche Represented at House of Commons Sub-Committee on Food Safety
9. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
10. Bioniche Reports Fiscal 2009 Third Quarter
11. Bioniche Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively ... any logo with a glitch reveal in just a few clicks of a mouse. Customizable ... of each preset. Use these presets to add a uniquely animated logo to any photos ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... South Africa , Feb. 20, 2017  There ... illness and non-communicable diseases (NCDs) across sub-Saharan Africa, which ... drugs. The growing incidence of more Western lifestyle diseases ... disease, in addition to infectious and parasitic illness, will ... with a business opportunity of $40.8 billion in ...
(Date:2/20/2017)... According to a new market research report "Pulmonary/ Respiratory Drug ... dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications ... to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in ... Continue Reading ... ...
(Date:2/20/2017)... --  Alberty   Drugs , a leading ... has announced a significant shift in focus by concentrating ... servicing local Veteran Affairs Centers (VA) and other Federal ... need to secure cost effective treatments for their patients, ... their goods & services. "The opportunity to ...
Breaking Medicine Technology: